{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:46Z","timestamp":1793998066699,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The addition of SGLT2i to insulin therapy in type 1 diabetes (T1D) is an emerging treatment strategy. This study evaluates the real-world effects of SGLT2i on glycaemic control and other outcomes in individuals with T1D.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this single-center retrospective study, we included 78 adults with T1D who initiated SGLT2i and were observed for up to 24 months. Data included demographics, laboratory values, diabetic complications, and ongoing therapy. The primary outcome was the change in HbA1c over time. Persistence on therapy and adverse events were also recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean age was 47.2 years, diabetes duration 24.6 years, baseline HbA1c 8.3%, and BMI 29.8\u00a0kg\/m<jats:sup>2<\/jats:sup>. The median persistence on therapy was 14.8 months. HbA1c reduction was significantly associated with persistence (<jats:italic>p<\/jats:italic>\u2009=\u20090.01), with a maximum decrease of 0.61% at 6 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Time in range improved by 13.7% at 3 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Persistent users experienced a maximum weight loss of 2.5\u00a0kg at 9 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Insulin doses declined significantly (max 15% at 21 months). UACR declined significantly at 15 months (<jats:italic>p<\/jats:italic>\u2009=\u20090.025). Treatment discontinuation due to adverse events (mainly genitourinary tract infections) occurred in 25.6% of patients, and 1 episode of diabetic ketoacidosis was recorded. A review of the literature suggests that the observed effects are within the range of benefits reported previously from different countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SGLT2i addition to insulin therapy in T1D patients resulted in sustained HbA1c reductions and weight loss. Therapy persistence significantly influenced outcomes, underscoring the importance of patient selection and monitoring for adverse effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-025-02602-8","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:20:28Z","timestamp":1746847228000},"page":"1759-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence"],"prefix":"10.1007","volume":"48","author":[{"given":"Alberto","family":"Maran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Boscari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fagarazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Crepaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vedovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta Maria","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bruttomesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Luca","family":"Morieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"2602_CR1","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.2337\/dci22-0018","volume":"45","author":"JL Sherr","year":"2022","unstructured":"Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M (2022) Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European association for the study of diabetes and the American diabetes association. Diabetes Care 45:3058\u20133074","journal-title":"Diabetes Care"},{"key":"2602_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/dia.2019.0027","volume":"21","author":"JH Pettus","year":"2019","unstructured":"Pettus JH, Kushner JA, Valentine V, Wood R, Pang C, Paranjape S, Berria R, Deluzio A, Edelman SE (2019) Adjunct therapy in type 1 diabetes: A survey to uncover unmet needs and patient preferences beyond HbA1c measures. Diabetes Technol Ther 21:336\u2013343","journal-title":"Diabetes Technol Ther"},{"key":"2602_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/13543784.2022.2159806","volume":"31","author":"JG Timmons","year":"2022","unstructured":"Timmons JG, Littlejohn L, Boyle JG, Petrie JR (2022) Recent developments in adjunct therapies for type 1 diabetes. Expert Opin Investig Drugs 31:1311\u20131320","journal-title":"Expert Opin Investig Drugs"},{"key":"2602_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","volume":"14","author":"P Fioretto","year":"2015","unstructured":"Fioretto P, Giaccari A, Sesti G (2015) Efficacy and safety of Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 14:142","journal-title":"Cardiovasc Diabetol"},{"key":"2602_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.14248","volume":"23","author":"M Phillip","year":"2021","unstructured":"Phillip M, Mathieu C, Lind M, Araki E, di Bartolo P, Bergenstal R, Heller S, Hansen L, Scheerer MF, Thoren F, Arya N, Xu J, Iqbal N, Dandona P (2021) Long-term efficacy and safety of Dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and\u2013\u20092 studies. Diabetes Obes Metab 23:549\u2013560","journal-title":"Diabetes Obes Metab"},{"key":"2602_CR6","unstructured":"European Medicines Agenxy (2019) First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. https:\/\/www.emaeuropaeu\/en\/news\/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes"},{"key":"2602_CR7","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41:2560\u20132569","journal-title":"Diabetes Care"},{"key":"2602_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2337\/dci19-0008","volume":"42","author":"JI Wolfsdorf","year":"2019","unstructured":"Wolfsdorf JI, Ratner RE (2019) SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care 42:991\u2013993","journal-title":"Diabetes Care"},{"key":"2602_CR9","doi-asserted-by":"crossref","unstructured":"Hussain S, Nathan H, Rowles S (2022) Dapagliflozin use in type 1 diabetes: industry, business and ethics. Brit J Diabetes;22","DOI":"10.15277\/bjd.2022.344"},{"key":"2602_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/dom.16149","volume":"27","author":"C Baechle","year":"2025","unstructured":"Baechle C, Rosenbauer J, Stahl-Pehe A, Seufert J, Mader JK, Wagner C, Wosch FJ, Erath D, Holl RW, Lanzinger S (2025) Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study. Diabetes Obes Metab 27:1591\u20131596","journal-title":"Diabetes Obes Metab"},{"key":"2602_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/dia.2019.0316","volume":"22","author":"A Bayona Cebada","year":"2020","unstructured":"Bayona Cebada A, Nattero-Chavez L, Alonso Diaz S, Escobar-Morreale HF, Luque-Ramirez M (2020) Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an Off-Label use protocol for clinical practice. Diabetes Technol Ther 22:208\u2013215","journal-title":"Diabetes Technol Ther"},{"key":"2602_CR12","doi-asserted-by":"publisher","first-page":"101501","DOI":"10.1016\/j.diabet.2023.101501","volume":"50","author":"M Duran-Martinez","year":"2024","unstructured":"Duran-Martinez M, Azriel S, Doulatram-Gamgaram VK, Moreno-Perez O, Pines-Corrales PJ, Tejera-Perez C, Merino-Torres JF, Brito-Sanfiel M, Chico A, Marco A, Garcia-Fernandez E, Martinez-Montoro JI (2024) Real-world safety and effectiveness of Dapagliflozin in people living with type 1 diabetes in Spain: the Dapa-ON multicenter retrospective study. Diabetes Metab 50:101501","journal-title":"Diabetes Metab"},{"key":"2602_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1210\/clinem\/dgac618","volume":"108","author":"K Edwards","year":"2023","unstructured":"Edwards K, Li X, Lingvay I (2023) Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A Real-World study. J Clin Endocrinol Metab 108:920\u2013930","journal-title":"J Clin Endocrinol Metab"},{"key":"2602_CR14","doi-asserted-by":"publisher","first-page":"215013271989518","DOI":"10.1177\/2150132719895188","volume":"10","author":"L El Hage","year":"2019","unstructured":"El Hage L, Kashyap SR, Rao P (2019) Use of SGLT-2 inhibitors in patients with type 1 diabetes mellitus. J Prim Care Community Health 10:2150132719895188","journal-title":"J Prim Care Community Health"},{"key":"2602_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-0041-1742196","volume":"12","author":"W Fallatah","year":"2022","unstructured":"Fallatah W, Brema I, Alobedallah A, Alkhathami R, Zaheer S, AlMalki E, Almehthel M, Alzahrani S, AlMalki MH (2022) Efficacy and safety of SGLT2 inhibitors as adjunctive treatment in type 1 diabetes in a tertiary care center in Saudi Arabia. Avicenna J Med 12:10\u201315","journal-title":"Avicenna J Med"},{"key":"2602_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2337\/dc19-1481","volume":"43","author":"C Hampp","year":"2020","unstructured":"Hampp C, Swain RS, Horgan C, Dee E, Qiang Y, Dutcher SK, Petrone A, Chen Tilney R, Maro JC, Panozzo CA (2020) Use of Sodium-Glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis. Diabetes Care 43:90\u201397","journal-title":"Diabetes Care"},{"key":"2602_CR17","doi-asserted-by":"publisher","first-page":"110794","DOI":"10.1016\/j.diabres.2023.110794","volume":"202","author":"J Hironaka","year":"2023","unstructured":"Hironaka J, Okada H, Hamaguchi M, Sakai K, Minamida M, Kondo Y, Hashimoto Y, Kitagawa N, Yano M, Yamazaki M, Hasegawa G, Horiguchi G, Teramukai S, Fukui M (2023) Effects of Dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort. Diabetes Res Clin Pract 202:110794","journal-title":"Diabetes Res Clin Pract"},{"key":"2602_CR18","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/jdi.13506","volume":"12","author":"T Horii","year":"2021","unstructured":"Horii T, Oikawa Y, Atsuda K, Shimada A (2021) On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. J Diabetes Investig 12:1586\u20131593","journal-title":"J Diabetes Investig"},{"key":"2602_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc21-1584","volume":"45","author":"A Palanca","year":"2022","unstructured":"Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: A European Two-Center experience. Diabetes Care 45:650\u2013658","journal-title":"Diabetes Care"},{"key":"2602_CR20","doi-asserted-by":"publisher","first-page":"e14764","DOI":"10.1111\/dme.14764","volume":"39","author":"A Raj","year":"2022","unstructured":"Raj A, Bansiya V, Evans ML, Boughton CK (2022) Implementation of Dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real-world experience. Diabet Med 39:e14764","journal-title":"Diabet Med"},{"key":"2602_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1507\/endocrj.EJ21-0161","volume":"68","author":"M Shimoda","year":"2021","unstructured":"Shimoda M, Mashiko A, Katakura Y, Sanada J, Fushimi Y, Obata A, Kimura T, Kohara K, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H (2021) Efficacy and safety of adding Ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. Endocr J 68:1455\u20131461","journal-title":"Endocr J"},{"key":"2602_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2478\/enr-2023-0018","volume":"57","author":"VB Silva","year":"2023","unstructured":"Silva VB, Fonseca L, Duarte DB, Puga FM, Assuncao G, Garrido S, Teixeira S, Vilaverde J, Cardoso MH (2023) Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study. Endocr Regul 57:144\u2013151","journal-title":"Endocr Regul"},{"key":"2602_CR23","doi-asserted-by":"publisher","first-page":"147916412211300","DOI":"10.1177\/14791641221130043","volume":"19","author":"EB Stougaard","year":"2022","unstructured":"Stougaard EB, Kristensen PL, Kielgast U, Andersen HU, Hamid Y, Gaede PH, Sondergaard E, Dorflinger GH, Fjeldborg KK, Hansen KW, Thomsen HH, Al-Imar TMJ, Roder M, Sridhar VS, Cherney D, Rossing P, Persson F (2022) Real life evaluation of sodium-glucose cotransporter 2 Inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. Diab Vasc Dis Res 19:14791641221130043","journal-title":"Diab Vasc Dis Res"},{"key":"2602_CR24","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/jdi.13240","volume":"11","author":"D Suzuki","year":"2020","unstructured":"Suzuki D, Yamada H, Yoshida M, Funazaki S, Amamoto M, Morimoto J, Hara K (2020) Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study. J Diabetes Investig 11:1230\u20131237","journal-title":"J Diabetes Investig"},{"key":"2602_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.17925\/EE.2021.17.1.12","volume":"17","author":"JH Jendle","year":"2021","unstructured":"Jendle JH, Ampudia-Blasco FJ, Fuchtenbusch M, Pozzilli P (2021) Dapagliflozin as an adjunct therapy to insulin in patients with type 1 diabetes mellitus: efficacy and safety of this combination. TouchREV Endocrinol 17:12\u201320","journal-title":"TouchREV Endocrinol"},{"key":"2602_CR26","doi-asserted-by":"publisher","first-page":"106396","DOI":"10.1016\/j.phrs.2022.106396","volume":"183","author":"ME Lunati","year":"2022","unstructured":"Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P (2022) SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res 183:106396","journal-title":"Pharmacol Res"},{"key":"2602_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.13012","volume":"20","author":"BM Bonora","year":"2018","unstructured":"Bonora BM, Avogaro A, Fadini GP (2018) Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab 20:25\u201333","journal-title":"Diabetes Obes Metab"},{"key":"2602_CR28","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.2337\/dc23-0083","volume":"46","author":"JI Martinez-Montoro","year":"2023","unstructured":"Martinez-Montoro JI, Picon-Cesar MJ, Simon-Frapolli VJ, Pinzon-Martin JL, Garcia-Aleman J, Duran-Martinez M, Tinahones FJ (2023) Evaluation of the clinical impact of Dapagliflozin discontinuation as adjunctive therapy for patients with type 1 diabetes after indication withdrawal: A Two-Center retrospective study. Diabetes Care 46:e101\u2013e102","journal-title":"Diabetes Care"},{"key":"2602_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","volume":"8","author":"PH Groop","year":"2020","unstructured":"Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto E, Mathieu C (2020) Effect of Dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol 8:845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2602_CR30","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.2337\/dc23-0129","volume":"46","author":"VS Sridhar","year":"2023","unstructured":"Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI (2023) The effects of Sotagliflozin in type 1 diabetes on clinical markers associated with cardiorenal protection: an exploratory analysis of inTandem3. Diabetes Care 46:e133\u2013e135","journal-title":"Diabetes Care"},{"key":"2602_CR31","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N (2021) Kidney effects of empagliflozin in people with type 1 diabetes. Clin J Am Soc Nephrol 16:1715\u20131719","journal-title":"Clin J Am Soc Nephrol"},{"key":"2602_CR32","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1210\/clinem\/dgae044","volume":"109","author":"HS Shah","year":"2024","unstructured":"Shah HS, McGill JB, Hirsch IB, Wu C, Galecki A, de Boer IH, Mauer M, Doria A (2024) Poor glycemic control is associated with more rapid kidney function decline after the onset of diabetic kidney disease. J Clin Endocrinol Metab 109:2124\u20132135","journal-title":"J Clin Endocrinol Metab"},{"key":"2602_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","volume":"17","author":"JR Weinstein","year":"2010","unstructured":"Weinstein JR, Anderson S (2010) The aging kidney: physiological changes. Adv Chronic Kidney Dis 17:302\u2013307","journal-title":"Adv Chronic Kidney Dis"},{"key":"2602_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-020-01368-5","volume":"44","author":"A Avogaro","year":"2021","unstructured":"Avogaro A, Azzolina D, Fadini GP, Baldi I (2021) Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. J Endocrinol Invest 44:745\u2013753","journal-title":"J Endocrinol Invest"},{"key":"2602_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U (2023) SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia 66:1869\u20131881","journal-title":"Diabetologia"},{"key":"2602_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1177\/19322968231152236","volume":"18","author":"J Huang","year":"2024","unstructured":"Huang J, Yeung AM, Bergenstal RM, Castorino K, Cengiz E, Dhatariya K, Niu I, Sherr JL, Umpierrez GE, Klonoff DC (2024) Update on measuring ketones. J Diabetes Sci Technol 18:714\u2013726","journal-title":"J Diabetes Sci Technol"},{"key":"2602_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2337\/dc13-1663","volume":"37","author":"F D\u2019Addio","year":"2014","unstructured":"D\u2019Addio F, Maffi P, Vezzulli P, Vergani A, Mello A, Bassi R, Nano R, Falautano M, Coppi E, Finzi G, D\u2019Angelo A, Fermo I, Pellegatta F, La Rosa S, Magnani G, Piemonti L, Falini A, Folli F, Secchi A, Fiorina P (2014) Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes. Diabetes Care 37:267\u2013276","journal-title":"Diabetes Care"},{"key":"2602_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2337\/dc11-1697","volume":"35","author":"P Fiorina","year":"2012","unstructured":"Fiorina P, Vezzulli P, Bassi R, Gremizzi C, Falautano M, D\u2019Addio F, Vergani A, Chabtini L, Altamura E, Mello A, Caldara R, Scavini M, Magnani G, Falini A, Secchi A (2012) Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation. Diabetes Care 35:367\u2013374","journal-title":"Diabetes Care"},{"key":"2602_CR39","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.numecd.2022.07.003","volume":"32","author":"D Pitocco","year":"2022","unstructured":"Pitocco D, Laurenzi A, Tomaselli L, Assaloni R, Consoli A, Di Bartolo P, Guardasole V, Lombardo F, Maffeis C, Rossi A, Gesuita R, Di Molfetta S, Rigamonti A, Scaramuzza A, Irace C, Cherubini V (2022) Health care organization and use of technological devices in people with diabetes in Italy: results from a survey of the working group on diabetes and technology. Nutr Metab Cardiovasc Dis 32:2392\u20132398","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02602-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:27:23Z","timestamp":1757168843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2602"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02602-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM received lecture fees from Novo Nordisk. FB received grants, honoraria or lecture fees from Novo Nordisk, Roche, Sanofi Aventis, Glooko, Tandem, Movi. BMB received lecture or advisory board fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, MSD, Sanofi, Servier, Novo-Nordisk. DB has received honoraria or lecture fees from Abbott, Roche Diabetes Care, Sanofi, Theras. MLM has received lecture or consultancy fee from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Guidotti, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi and Servier. GPF received grants, honoraria or lecture fees from AstraZeneca, Boehringer, Lilly, Guidotti, Mundipharma, Novartis, Novo Nordisk, Servier, Sanofi. MCC, MD, and CF have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}